pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Summit Therapeutics Inc. ($SMMT) · news · pharmadog
← back to Summit Therapeutics Inc.
News mentioning $SMMT
87
stories
2d
This week in charts: Biotech investors’ China bets are already paying off
biopharma dive
2d
FDA’s search for a new leader, and China’s largest drugmakers
stat
4d
STAT+: FDA discloses reasons for rejecting Summit drug
stat
4d
FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK
biopharma dive
4d
Summit’s rejection letter reveals FDA’s deeper concerns about trial design, safety
biospace
4d
Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlight
biospace
4d
5 acquisitions that forced Big Pharmas to co-parent
biospace
5d
FDA letter rejecting Summit cancer drug cites ‘modest’ benefit in data compared with toxicity risk
endpoints
5d
FDA’s complete response letter for Summit’s ivonescimab cites China-heavy data beyond survival miss
fiercebiotech
6d
Summit shares fall as FDA rejects closely watched PD-1/VEGF drug
biopharma dive
6d
FDA’s Summit rejection puts PD-1xVEGF class on notice to establish overall survival
biospace
6d
STAT+: Helus’ psychedelic drug improved depression in study but faces safety questions
stat
6d
STAT+: Bladder cancer immunotherapy from CG Oncology reduced risk of tumor recurrence
stat
6d
STAT+: Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues
stat
6d
BeOne, Hengrui top list of China’s most powerful drugmakers
stat
6d
STAT+: Apple and OpenEvidence launch experimental health chat app
stat
7d
STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics
stat
7d
Summit's PD-1xVEGF rejected by FDA in lung cancer
biospace
7d
FDA rejects Summit, Akeso's ivonescimab in narrow lung cancer setting
endpoints
9d
FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
fiercebiotech
10d
Chutes & Ladders—Bristol Myers' research chief out amid R&D reorganization
fiercebiotech
11d
Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November
biospace
11d
China has a clear shot to 2030 goals, though economic, cultural barriers remain
biospace
16d
Verdicts for Summit/Akeso, Capricor, Vertex mark FDA’s stacked November
biospace
17d
RevMed’s Rasonque shatters analyst estimates with $198M quarter
biospace
18d
6 potential blockbusters that could pave China’s path to 2030 ambitions
biospace
20d
OpenAI-funded Biossil snags Theriva's unwanted antibiotic degrader portfolio for up to $91M
fiercebiotech
20d
Drugmakers rush to pair up with Summit’s ivonescimab ahead of key verdict
biospace
23d
AstraZeneca employs $1.5B cost savings to reinvest back into growth
biospace
28d
#ESMO26: Akeso details ivonescimab's biliary cancer success, drawing Keytruda comparisons
endpoints
← prev
page 1 of 3
next →